Physician profile
Selim R Benbadis
NPI 1710902689
$2,092,223.31
in general payments reported to CMS, 2019-2025
32 companies · $323K in 2025
The $323K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312K · 2020: $167K · 2021: $311K · 2022: $328K · 2023: $318K · 2024: $334K · 2025: $323K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $594K · Honoraria: $172K · Travel and Lodging: $138K · Consulting Fee: $42K · Food and Beverage: $28K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $594,491.75 |
| Honoraria | $172,430.00 |
| Travel and Lodging | $138,126.41 |
| Consulting Fee | $41,663.59 |
| Food and Beverage | $28,410.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $369,163.28 | 2020-2025 | Xcopri |
| Ucb, INC. | $365,425.25 | 2022-2025 | Fintepla, Briviact, Nayzilam |
| Neurelis, INC. | $282,186.17 | 2020-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $221,954.23 | 2022-2025 | Epidiolex |
| Eisai INC. | $218,239.02 | 2019-2023 | |
| Greenwich Biosciences, INC. | $199,180.78 | 2019-2021 | |
| Livanova USA, INC. | $152,021.11 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Catalyst Pharmaceuticals, INC. | $97,026.47 | 2023-2025 | Fycompa |
| Sunovion Pharmaceuticals INC. | $85,126.87 | 2019-2022 | |
| Gw Pharma Limited | $27,285.50 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $20,970.22 | 2023-2024 | Aptiom |
| Takeda Pharmaceuticals U.S.A., INC. | $18,997.58 | 2022-2024 | |
| Ucb Sa | $7,772.11 | 2025 | Fintepla |
| Aquestive Therapeutics, INC. | $7,650.00 | 2020-2022 | |
| Acadia Pharmaceuticals INC | $4,036.17 | 2025 | Daybue |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $2,726.66 | 2019-2021 | |
| Ucb Gmbh | $2,625.00 | 2023 | |
| Aucta Pharmaceuticals, INC. | $2,598.17 | 2025 | Motpoly Xr |
| Ceribell, INC. | $2,197.97 | 2019-2024 | Pocket Eeg Device |
| Otter Pharmaceuticals, LLC | $1,761.00 | 2024 | Sympazan |
| Neuropace, INC. | $1,494.88 | 2019-2025 | |
| Medtronic USA, INC. | $1,138.42 | 2019 | |
| Immedica Pharma US, INC. | $310.51 | 2023 | |
| Zogenix INC. | $123.04 | 2021 | |
| Biocodex, INC. | $116.16 | 2021-2024 | |
| Monteris Medical Corporation | $52.74 | 2022 | |
| Spark Therapeutics, INC. | $22.66 | 2022 | |
| Medtronic, INC. | $21.34 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Selim Benbadis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.